| Literature DB >> 22844331 |
Chia Ju Chang1, Thing-Fong Tzeng, Shorong-Shii Liou, Yuan-Shiun Chang, I-Min Liu.
Abstract
The present study evaluated the potential genotoxicity of the ethanol extracts from the rhizome of Zingiber zerumbet (L.) Smith (EEZZR) using a standard battery of tests. Chemical analysis with liquid chromatography-tandem mass spectrometry revealed that EEZZR contained Zerumbone (200.3 ± 0.37 μg/g) and 6-gingerol (102.5 ± 0.28 μg/g). There were no increases in the number of revertant colonies with EEZZR at concentrations of 150-5000 μg per plate, regardless of the metabolic activation system (S-9 mix) used in the histidine-dependent auxotrophic mutants of Salmonella typhimurium (strains TA97, TA98, TA100, TA102, and TA1535) compared to the vehicle control. Furthermore, EEZZR at doses of 150-5000 μg mL(-1) did not increase the number of structural aberrations in Chinese hamster lung cells in the presence or absence of S-9 mix. An oral administration of EEZZR to ICR mice, with doses of up to 2000 mg/kg, caused no significant increases in the number of micronucleated polychromatic erythrocytes (MNPCEs) and mean ratio of polychromatic erythrocytes to total erythrocytes. Lastly, RZZEE did not increase the incidence of MNPCEs in bone marrow. Based on these findings, it may be concluded that the use of EEZZR in traditional medicine poses no risk of genotoxicity.Entities:
Year: 2012 PMID: 22844331 PMCID: PMC3403701 DOI: 10.1155/2012/406296
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1LC/MS/MS chromatogram for (a) zerumbone and (b) 6-gingerol in RZZEE sample.
Results of bacterial reverse mutation assay.
| Treatments | Dose ( | Revertant colonies per plate | ||||
|---|---|---|---|---|---|---|
| TA97 | TA98 | TA100 | TA102 | TA1535 | ||
| EEZZR without S9 | 0 | 156 ± 12 | 20 ± 3 | 105 ± 10 | 274 ± 12 | 13 ± 3 |
| 150 | 167 ± 14 | 22 ± 2 | 110 ± 8 | 282 ± 14 | 15 ± 4 | |
| 300 | 166 ± 10 | 21 ± 3 | 105 ± 11 | 276 ± 18 | 14 ± 3 | |
| 600 | 173 ± 18 | 20 ± 5 | 104 ± 9 | 268 ± 17 | 12 ± 5 | |
| 1250 | 176 ± 11 | 22 ± 2 | 112 ± 12 | 276 ± 10 | 14 ± 6 | |
| 2500 | 169 ± 16 | 23 ± 4 | 108 ± 15 | 258 ± 13 | 14 ± 8 | |
| 5000 | 168 ± 11 | 21 ± 7 | 103 ± 16 | 261 ± 11 | 13 ± 6 | |
|
| ||||||
| EEZZR with S9 | 0 | 177 ± 16 | 21 ± 4 | 105 ± 12 | 282 ± 14 | 15 ± 4 |
| 150 | 183 ± 14 | 23 ± 3 | 110 ± 11 | 290 ± 18 | 16 ± 5 | |
| 300 | 188 ± 17 | 22 ± 6 | 105 ± 15 | 284 ± 17 | 15 ± 7 | |
| 600 | 186 ± 12 | 21 ± 4 | 104 ± 12 | 276 ± 12 | 14 ± 6 | |
| 1250 | 197 ± 15 | 23 ± 6 | 112 ± 14 | 287 ± 13 | 17 ± 8 | |
| 2500 | 182 ± 14 | 24 ± 7 | 108 ± 16 | 265 ± 15 | 16 ± 9 | |
| 5000 | 191 ± 16 | 22 ± 6 | 103 ± 13 | 268 ± 16 | 16 ± 4 | |
|
| ||||||
| Positive controls | ||||||
| 2-AF with S9 | 10 | 1260 ± 48 | 966 ± 36 | |||
| 2-AA with S9 | 1 | 697 ± 21 | 847 ± 29 | 127 ± 18 | ||
| 9-AA without S9 | 0.2 | 1096 ± 32 | ||||
| 2-AF without S9 | 0.1 | 993 ± 28 | ||||
| SA without S9 | 0.5 | 774 ± 33 | 508 ± 27 | |||
| MMC without S9 | 0.5 | 1640 ± 52 | ||||
Values are mean ± SD of 3 plates.
Results of the chromosomal aberration assay in CHL cells.
| Exposure (h)/±S9 | Dose ( | Structural aberrations | Numerical aberrations | Cell growth (%) | ||
|---|---|---|---|---|---|---|
| Chromatid break | Chromatid exchange | Polyploidy | Endoreduplication | |||
| 6/+S9 | 0 | 1 | 0 | 1 | 0 | 100 |
| 150 | 2 | 0 | 1 | 0 | 99.2 | |
| 300 | 2 | 0 | 1 | 0 | 98.3 | |
| 600 | 1 | 0 | 0 | 0 | 99.4 | |
| 1250 | 2 | 0 | 1 | 0 | 98.5 | |
| 2500 | 1 | 0 | 0 | 0 | 99.1 | |
| 5000 | 3 | 1 | 1 | 0 | 97.8 | |
| B[a]P 0.2 | 25 | 37 | 6 | 2 | 61.3 | |
|
| ||||||
| 6/−S9 | 0 | 1 | 0 | 0 | 0 | 100 |
| 150 | 3 | 0 | 2 | 0 | 99.3 | |
| 300 | 3 | 0 | 1 | 0 | 98.2 | |
| 600 | 2 | 0 | 1 | 0 | 97.6 | |
| 1250 | 2 | 0 | 1 | 0 | 98.1 | |
| 2500 | 3 | 0 | 0 | 0 | 97.4 | |
| 5000 | 3 | 1 | 0 | 0 | 96.5 | |
| B[a]P 0.15 | 25 | 36 | 5 | 2 | 57.2 | |
|
| ||||||
| 24/−S9 | 0 | 0 | 0 | 1 | 0 | 100 |
| 150 | 4 | 0 | 1 | 0 | 99.3 | |
| 300 | 3 | 0 | 2 | 0 | 97.9 | |
| 600 | 1 | 0 | 0 | 0 | 98.2 | |
| 1250 | 2 | 0 | 1 | 0 | 96.8 | |
| 2500 | 1 | 0 | 0 | 0 | 97.4 | |
| 5000 | 3 | 0 | 2 | 0 | 98.6 | |
| MMC 0.05 | 36 | 44 | 3 | 1 | 62.3 | |
|
| ||||||
| 48/−S9 | 0 | 0 | 0 | 1 | 100 | |
| 150 | 0 | 0 | 0 | 0 | 99.6 | |
| 300 | 1 | 0 | 1 | 0 | 98.2 | |
| 600 | 3 | 0 | 1 | 0 | 98.1 | |
| 1250 | 3 | 0 | 0 | 0 | 97.9 | |
| 2500 | 1 | 0 | 0 | 0 | 98.2 | |
| 5000 | 1 | 0 | 1 | 0 | 97.6 | |
| MMC 0.05 | 26 | 0 | 4 | 1 | 60.4 | |
Results of micronucleus test.
| Treatments | Dose (mg kg−1) | MNPCE/2000 PCEs | PCE/(PCE + NCE) |
|---|---|---|---|
| Vehicle | 0 | 1.66 ± 1.05 | 0.52 ± 0.03 |
| EEZZR | 500 | 1.65 ± 1.13 | 0.54 ± 0.05 |
| 1000 | 1.58 ± 0.98 | 0.52 ± 0.04 | |
| 2000 | 1.60 ± 1.11 | 0.51 ± 0.06 | |
| CPA | 70 | 62.31 ± 5.02* | 0.42 ± 0.09 |
Data are presented as mean ± SD from twelve mice (6 male mice and 6 female mice) per dose group. Since there was no difference between males and females within the same dose group, Table 3 shows the combined data for males and females. ∗Significantly different from the control at P < 0.05. Bone marrow cells were harvested 24 h after the last oral dose of EEZZR or CPA injection.